Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies

S. R. Levine, Robin L Brey, C. L M Joseph, S. Havstad

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Antiphospholipid antibodies are a marker for an increased risk of thrombosis, including stroke and transient ischemic attacks. Prior studies suggest that patients with these antibodies and thrombosis may be at increased risk for recurrent thrombotic events. We prospectively evaluated 75 patients with antiphospholipid antibodies and cerebral or ocular ischemia for recurrence of thrombosis. Twenty-six patients (35%) experienced a recurrent stroke or transient ischemic attack, with a mean time to recurrence of 1.18 years. Hypertension significantly increased the risk of a recurrent transient ischemic attack. Patients with coronary artery disease were three times as likely as those without to have a recurrent stroke or transient ischemic attack. There was a trend for treatment with a combination of aspirin and dipyridamole to reduce the risk of recurrent thrombotic events after adjusting for sex and ethnicity.

Original languageEnglish (US)
JournalStroke
Volume23
Issue number2 SUPPL.
StatePublished - 1992

Fingerprint

Antiphospholipid Antibodies
Transient Ischemic Attack
Brain Ischemia
Thrombosis
Stroke
Recurrence
Dipyridamole
Aspirin
Coronary Artery Disease
Ischemia
Hypertension
Antibodies
Therapeutics

Keywords

  • anticoagulants, anticardiolipin antibodies
  • cerebral ischemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. / Levine, S. R.; Brey, Robin L; Joseph, C. L M; Havstad, S.

In: Stroke, Vol. 23, No. 2 SUPPL., 1992.

Research output: Contribution to journalArticle

@article{e5a2811f7d1d48e3a9c24d875e2ef332,
title = "Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies",
abstract = "Antiphospholipid antibodies are a marker for an increased risk of thrombosis, including stroke and transient ischemic attacks. Prior studies suggest that patients with these antibodies and thrombosis may be at increased risk for recurrent thrombotic events. We prospectively evaluated 75 patients with antiphospholipid antibodies and cerebral or ocular ischemia for recurrence of thrombosis. Twenty-six patients (35{\%}) experienced a recurrent stroke or transient ischemic attack, with a mean time to recurrence of 1.18 years. Hypertension significantly increased the risk of a recurrent transient ischemic attack. Patients with coronary artery disease were three times as likely as those without to have a recurrent stroke or transient ischemic attack. There was a trend for treatment with a combination of aspirin and dipyridamole to reduce the risk of recurrent thrombotic events after adjusting for sex and ethnicity.",
keywords = "anticoagulants, anticardiolipin antibodies, cerebral ischemia",
author = "Levine, {S. R.} and Brey, {Robin L} and Joseph, {C. L M} and S. Havstad",
year = "1992",
language = "English (US)",
volume = "23",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies

AU - Levine, S. R.

AU - Brey, Robin L

AU - Joseph, C. L M

AU - Havstad, S.

PY - 1992

Y1 - 1992

N2 - Antiphospholipid antibodies are a marker for an increased risk of thrombosis, including stroke and transient ischemic attacks. Prior studies suggest that patients with these antibodies and thrombosis may be at increased risk for recurrent thrombotic events. We prospectively evaluated 75 patients with antiphospholipid antibodies and cerebral or ocular ischemia for recurrence of thrombosis. Twenty-six patients (35%) experienced a recurrent stroke or transient ischemic attack, with a mean time to recurrence of 1.18 years. Hypertension significantly increased the risk of a recurrent transient ischemic attack. Patients with coronary artery disease were three times as likely as those without to have a recurrent stroke or transient ischemic attack. There was a trend for treatment with a combination of aspirin and dipyridamole to reduce the risk of recurrent thrombotic events after adjusting for sex and ethnicity.

AB - Antiphospholipid antibodies are a marker for an increased risk of thrombosis, including stroke and transient ischemic attacks. Prior studies suggest that patients with these antibodies and thrombosis may be at increased risk for recurrent thrombotic events. We prospectively evaluated 75 patients with antiphospholipid antibodies and cerebral or ocular ischemia for recurrence of thrombosis. Twenty-six patients (35%) experienced a recurrent stroke or transient ischemic attack, with a mean time to recurrence of 1.18 years. Hypertension significantly increased the risk of a recurrent transient ischemic attack. Patients with coronary artery disease were three times as likely as those without to have a recurrent stroke or transient ischemic attack. There was a trend for treatment with a combination of aspirin and dipyridamole to reduce the risk of recurrent thrombotic events after adjusting for sex and ethnicity.

KW - anticoagulants, anticardiolipin antibodies

KW - cerebral ischemia

UR - http://www.scopus.com/inward/record.url?scp=0026605355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026605355&partnerID=8YFLogxK

M3 - Article

C2 - 1561671

AN - SCOPUS:0026605355

VL - 23

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 2 SUPPL.

ER -